CNS Activity
Sources: http://www.openaccessjournals.com/articles/lixisenatide-clinical-profile-and-available-evidence.pdf
Curator's Comment: Known to be CNS penetrant in rodents. Human data not available.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P43220 Gene ID: 2740.0 Gene Symbol: GLP1R Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ADLYXIN Approved UseADLYXIN is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date2016 |
Sample Use Guides
The starting dose of ADLYXIN is 10 mcg subcutaneously once daily for 14 days. Increase the dose to the maintenance dose of 20 mcg once daily starting on Day 15.
Route of Administration:
Other
In Vitro Use Guide
Curator's Comment: In vitro, lixisenatide bound to human glucagon-like peptide-1 receptor (GLP-1R) with a greater affinity than native human GLP-1 (7-36 amide). In various in vitro and in vivo models of T2DM, lixisenatide improved glycemic measures and demonstrated promising pancreatic beta-cell-preserving actions.
Unknown
| Substance Class |
Protein
Created
by
admin
on
Edited
Fri Dec 15 18:31:19 GMT 2023
by
admin
on
Fri Dec 15 18:31:19 GMT 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
74O62BB01U
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA10BX10
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
||
|
WHO-ATC |
A10BX10
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
||
|
WHO-ATC |
A10AE54
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
||
|
WHO-ATC |
A10BJ03
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
||
|
NDF-RT |
N0000178480
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
320367-13-3
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
85662
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
CHEMBL2108336
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
1440051
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | RxNorm | ||
|
C166988
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
LYXUMIA
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | APPROVED JUNE 2013 | ||
|
7387
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
Lixisenatide
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
74O62BB01U
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
SUB32251
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
AB-118
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
74O62BB01U
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
DTXSID301029581
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
m6875
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000124357
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
Lixisenatide
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
DB09265
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
4815
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY | |||
|
8970
Created by
admin on Fri Dec 15 18:31:19 GMT 2023 , Edited by admin on Fri Dec 15 18:31:19 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:CALCULATED | CHEMICAL |
|
||||
| Tmax | PHARMACOKINETIC |
|
SUBCUTANEOUS ADMINISTRATION |
|
||
| Volume of Distribution | PHARMACOKINETIC |
|
|
|||
| Molecular Formula | CHEMICAL |
|
||||
| Biological Half-life | PHARMACOKINETIC |
|
|
|||